Shares of vTv Therapeutics Inc (NASDAQ:VTVT) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $18.40.
A number of equities analysts recently commented on VTVT shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $12.00 price objective on shares of vTv Therapeutics in a research note on Friday, November 3rd. Citigroup reaffirmed an “add” rating on shares of vTv Therapeutics in a research note on Wednesday, November 8th. Canaccord Genuity set a $15.00 target price on vTv Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Northland Securities initiated coverage on vTv Therapeutics in a report on Thursday, February 8th. They issued an “outperform” rating and a $28.00 target price for the company.
vTv Therapeutics (NASDAQ:VTVT) opened at $6.63 on Friday. The company has a market capitalization of $217.54, a P/E ratio of -4.02 and a beta of 1.11. vTv Therapeutics has a 12 month low of $3.57 and a 12 month high of $8.40.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $114,000. Millennium Management LLC bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $377,000. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the third quarter valued at approximately $481,000. State Street Corp increased its holdings in shares of vTv Therapeutics by 2.1% during the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Royce & Associates LP bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $1,352,000. Hedge funds and other institutional investors own 11.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2018/02/19/analysts-set-vtv-therapeutics-inc-vtvt-target-price-at-18-40.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.